Pacific Sun Financial Corp Reduces Stock Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Pacific Sun Financial Corp lowered its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 7.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,293 shares of the company’s stock after selling 475 shares during the quarter. Pacific Sun Financial Corp owned 0.16% of Invesco Biotechnology & Genome ETF worth $419,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Massachusetts Wealth Management boosted its holdings in Invesco Biotechnology & Genome ETF by 1.3% in the fourth quarter. Massachusetts Wealth Management now owns 18,414 shares of the company’s stock worth $1,225,000 after purchasing an additional 230 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its holdings in Invesco Biotechnology & Genome ETF by 5.6% in the third quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock worth $393,000 after purchasing an additional 299 shares during the last quarter. Howe & Rusling Inc. purchased a new stake in Invesco Biotechnology & Genome ETF in the third quarter worth approximately $31,000. IHT Wealth Management LLC boosted its holdings in Invesco Biotechnology & Genome ETF by 14.7% in the third quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock worth $847,000 after purchasing an additional 1,550 shares during the last quarter. Finally, HighTower Advisors LLC boosted its holdings in Invesco Biotechnology & Genome ETF by 64.1% in the third quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock worth $494,000 after purchasing an additional 2,774 shares during the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

Shares of Invesco Biotechnology & Genome ETF stock opened at $68.37 on Thursday. The company’s fifty day simple moving average is $68.18 and its 200-day simple moving average is $69.10. The stock has a market capitalization of $276.21 million, a PE ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 1-year low of $59.32 and a 1-year high of $72.84.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.